Premenopausal breast cancer
Information
- Disease name
- Premenopausal breast cancer
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03407768 | Active, not recruiting | N/A | Role of Individualized Intervention(s) in Hormone-Receptor Positive Early-stage Breast Cancer | July 1, 2018 | December 31, 2024 |
| NCT04997941 | Active, not recruiting | Phase 2 | Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients | October 21, 2021 | December 31, 2028 |
| NCT01546649 | Completed | Phase 3 | A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer | April 2012 | December 2014 |
| NCT03209518 | Completed | Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in "Premenopausal Breast Cancer" | March 18, 2016 | October 10, 2018 | |
| NCT06225284 | Not yet recruiting | Phase 2 | Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients | February 15, 2024 | December 2030 |
| NCT05801705 | Not yet recruiting | Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study | June 1, 2023 | December 30, 2023 | |
| NCT06458764 | Recruiting | Sexual Dysfunction Check-up in Premenopausal Breast Cancer Survivors Taking Endocrine Therapy: A Cross-Sectional Study | May 1, 2023 | March 1, 2025 | |
| NCT05333328 | Recruiting | Phase 4 | OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk | February 6, 2023 | January 2033 |
| NCT05720260 | Recruiting | Phase 2 | Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC | January 17, 2023 | January 31, 2027 |
| NCT05982093 | Recruiting | Phase 2 | Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer | October 3, 2023 | January 2025 |
| NCT02990845 | Terminated | Phase 1/Phase 2 | Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer | September 15, 2017 | August 16, 2022 |
| NCT01726322 | Terminated | Ovarian Reserve in Premenopausal Breast Cancer | September 2012 | July 13, 2020 |